Having already spoken to Generics Bulletin about the early days of his now decade-long tenure as director general of European off-patent industry association Medicines for Europe – in the first part of an exclusive three-part interview (see sidebar) – Adrian van den Hoven subsequently turned to reflect on the various successes and challenges that he and the organization have encountered over the past ten years.
First of all, van den Hoven spotlighted the enormous rise in prominence of biosimilars in Europe, and how this area compared to the organization’s previous experiences in promoting small-molecule generics.
